Call Us: 1 (800) 647 6100

6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps


6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps



People First Culture

XYMOGEN Awarded 2017 Central Florida Manufacturer of the Year

  •  by admin
  •  10/30/2017

On Oct. 12, 2017, XYMOGEN was honored with the prestigious 2017 Manufacturers Association of Central Florida’s (MACF) Award of Excellence for Manufacturer of the Year in the large manufacturer size category.

Read More  

XYMOGEN in Elite Group, Named Tenth Time to Inc. 5000

Orlando-based health sciences company XYMOGEN has recently been recognized for the tenth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation

Read More  

XYMOGEN Leads Amazon Elements on Supplement Transparency

XYMOGEN is way ahead of the supplements transparency curve. Recently, Amazon Elements, the mega internet retailer’s private label brand, has included four dietary supplements, in an effort, it states, to bring more transparency and safety to these products. As the only exclusive practitioner-channel supplements formula company, XYMOGEN has been offering this transparency to its customers for years.

Read More  

XYMOGEN Makes History

XYMOGEN, in partnership with FON Consulting, publishes a chronicle of the dramatic rise and influence of integrative healthcare.

Read More  

XYMOGEN®’s Omega MonoPure™ Delivers Three Times More Bioavailable Omega-3s Than Other Products on the Market

ORLANDO, Fla. — October 4, 2016 — XYMOGEN® rocks the nutraceutical industry yet again with the introduction of its patented and exclusive MonoPure™ line of omega-3 EPA + DHA products. What makes MonoPure™ so different from other omega-3 EPA + DHA products is that it delivers an easy to digest highly concentrated omega-3 fish oil, which when studied clinically was shown to be three times more absorbable* than ethyl ester (EE) fish oil.


Read More  

XYMOGEN to supply multivitamin preparation for prestigious, federally funded clinical Trial to Assess Chelation Therapy (TACT2)

ORLANDO, Fla. (September 27, 2016)—XYMOGEN is proud to announce that it has been chosen by Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to manufacture and supply the oral vitamin and mineral preparations that will be tested in the second Trial to Assess Chelation Therapy (TACT2), a $37M federally sponsored clinical trial.

Read More  


Latest Tweets

Become a XYMOGEN Insider

Join our mailing list.
Interested in receiving special offers, access to exclusive webinars, seminars, up-to-date industry news, and so much more? Sign up for our FREE newsletter and get started today!

BONUS: As a XYMOGEN Insider, you will also get a FREE digital copy of The Rise of Integrative Health & Medicine—The Milestones: 1963–Present by Glenn Sabin and Taylor Walsh.


Global Headquarters
Contact Us


©2017XYMOGEN®. All right reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.